Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was founded in 2017 and is headquartered in Waltham, Massachusetts.
IPO Year: 2020
Exchange: NASDAQ
Website: dyne-tx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/24/2025 | $13.00 | Mkt Perform | Bernstein |
| 6/11/2025 | $37.00 | Outperform | Raymond James |
| 6/2/2025 | $34.00 | Outperform | Oppenheimer |
| 5/29/2025 | $46.00 | Outperform | Evercore ISI |
| 3/12/2025 | $50.00 | Outperform | BMO Capital Markets |
| 3/7/2025 | $50.00 | Sector Outperform | Scotiabank |
| 12/13/2024 | $46.00 | Outperform | Robert W. Baird |
| 11/26/2024 | $45.00 | Outperform | RBC Capital Mkts |
| 10/24/2024 | $43.00 → $35.00 | Overweight → Neutral | JP Morgan |
| 5/21/2024 | $31.00 → $42.00 | Buy | Chardan Capital Markets |
Bernstein initiated coverage of Dyne Therapeutics with a rating of Mkt Perform and set a new price target of $13.00
Raymond James resumed coverage of Dyne Therapeutics with a rating of Outperform and set a new price target of $37.00
Oppenheimer resumed coverage of Dyne Therapeutics with a rating of Outperform and set a new price target of $34.00
Evercore ISI initiated coverage of Dyne Therapeutics with a rating of Outperform and set a new price target of $46.00
BMO Capital Markets initiated coverage of Dyne Therapeutics with a rating of Outperform and set a new price target of $50.00
Scotiabank initiated coverage of Dyne Therapeutics with a rating of Sector Outperform and set a new price target of $50.00
Robert W. Baird initiated coverage of Dyne Therapeutics with a rating of Outperform and set a new price target of $46.00
RBC Capital Mkts initiated coverage of Dyne Therapeutics with a rating of Outperform and set a new price target of $45.00
JP Morgan downgraded Dyne Therapeutics from Overweight to Neutral and set a new price target of $35.00 from $43.00 previously
Chardan Capital Markets reiterated coverage of Dyne Therapeutics with a rating of Buy and set a new price target of $42.00 from $31.00 previously
4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
424B5 - Dyne Therapeutics, Inc. (0001818794) (Filer)
8-K - Dyne Therapeutics, Inc. (0001818794) (Filer)
8-K - Dyne Therapeutics, Inc. (0001818794) (Filer)
144 - Dyne Therapeutics, Inc. (0001818794) (Subject)
144 - Dyne Therapeutics, Inc. (0001818794) (Subject)
144 - Dyne Therapeutics, Inc. (0001818794) (Subject)
144 - Dyne Therapeutics, Inc. (0001818794) (Subject)
8-K - Dyne Therapeutics, Inc. (0001818794) (Filer)
144 - Dyne Therapeutics, Inc. (0001818794) (Subject)
SCHEDULE 13G/A - Dyne Therapeutics, Inc. (0001818794) (Subject)
WALTHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the pricing of an underwritten public offering of 24,242,425 shares of its common stock at a public offering price of $8.25 per share. The gross proceeds to Dyne from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Dyne, are expected to be $200.0 million. All shares in the offering are being sold by Dyne. The offering is expected to close on or about July 2, 2025, subject to customary closing conditi
WALTHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has commenced an underwritten public offering of $200,000,000 of shares of its common stock. Dyne also intends to grant the underwriters a 30-day option to purchase up to an additional $30,000,000 of shares of its common stock. All of the shares in the proposed offering are to be sold by Dyne. Morgan Stanley, Jefferies, Stifel and Guggenheim Securities are acting as joint book-running managers for the offering. Jones is acting as co-manager for
- $100 million funded upfront; additional $175 million tied to milestones provides strategic flexibility through key inflection points - WALTHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced it has entered into a $275 million non-dilutive senior secured term loan facility with Hercules Capital, Inc. (NYSE:HTGC), a leader in customized debt financing for companies in the life sciences and technology-related markets. The transaction strengthens the company's balance sheet as it advances DYNE-101 and DYNE-251
- Based on Type C meeting and new data, Dyne submitted revised ACHIEVE trial protocol to FDA elevating vHOT to primary endpoint for U.S. Accelerated Approval - - New positive clinical data from Phase 1/2 ACHIEVE trial support vHOT as early indicator of clinical benefit with DYNE-101 in DM1 - - Ongoing Registrational Expansion Cohort in ACHIEVE trial to enroll 60 participants and include sites in U.S. - - Company to host an investor and analyst conference call today, June 17, at 8:00 a.m. ET - WALTHAM, Mass., June 17, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically
WALTHAM, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced it plans to provide an update on DYNE-101 in myotonic dystrophy type 1 (DM1) tomorrow, June 17, 2025, and to host a webcast at 8:00 a.m. ET. The company intends to issue a press release prior to the start of the event. Investor Conference Call and Webcast The live webcast will be available on the Events & Presentations page of the Investors & Media section of Dyne's website, and a replay will be accessible for 90 days followin
- DYNE-302 Demonstrated Functional Improvement in an FSHD Preclinical Model - WALTHAM, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced that it will be presenting new preclinical data demonstrating the potential of DYNE-302 to achieve functional improvement in facioscapulohumeral muscular dystrophy (FSHD). The data will be presented at the 32nd Annual FSHD Society's International Research Congress being held June 12-13, 2025, in Amsterdam. In a mouse model of severe FSHD, a single intravenous dose
- FDA (CDER) Type C meeting held in May 2025 for DYNE-101 in DM1 and Dyne plans to provide a regulatory update following receipt of meeting minutes - - Registrational Expansion Cohort of ACHIEVE Trial of DYNE-101 in DM1 initiated to support potential submission for U.S. Accelerated Approval in H1 2026 - - Registrational Expansion Cohort of DELIVER Trial of DYNE-251 in DMD fully enrolled to support potential submission for U.S. Accelerated Approval in early 2026 - WALTHAM, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven ne
- Recently presented data demonstrated sustained functional improvement with DYNE-251 treatment through 18 months - - Data from the fully enrolled DELIVER registrational expansion cohort is planned for late 2025 - WALTHAM, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced that the European Commission (EC) has granted orphan drug designation for DYNE-251 for the treatment of Duchenne muscular dystrophy (DMD). DYNE-251 is being evaluated in the Phase 1/2 DELIVER global clinical trial in individuals with
- Vikram Ranade, PhD, appointed as chief business officer - - Ranjan Batra, PhD, appointed as chief scientific officer - - Oxana Beskrovnaya, PhD, transitioning to chief innovation officer - WALTHAM, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced the appointments of Vikram (Vik) Ranade, PhD, as chief business officer (CBO) and Ranjan (Ron) Batra, PhD, as chief scientific officer (CSO) of Dyne. Dr. Ranade will lead business development, corporate strategy and strategic partnerships to support the co
WALTHAM, Mass., April 14, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to three new employees. The awards were approved by Dyne's Compensation Committee and made as an inducement material to the new employees' acceptance of employment with Dyne in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity awards consisted of non-statutory stock options to purchase up to an aggregate of 330,200 shares of Dyne's common stock at a per share exercise price equal t
- Based on Type C meeting and new data, Dyne submitted revised ACHIEVE trial protocol to FDA elevating vHOT to primary endpoint for U.S. Accelerated Approval - - New positive clinical data from Phase 1/2 ACHIEVE trial support vHOT as early indicator of clinical benefit with DYNE-101 in DM1 - - Ongoing Registrational Expansion Cohort in ACHIEVE trial to enroll 60 participants and include sites in U.S. - - Company to host an investor and analyst conference call today, June 17, at 8:00 a.m. ET - WALTHAM, Mass., June 17, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically
WALTHAM, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced it plans to provide an update on DYNE-101 in myotonic dystrophy type 1 (DM1) tomorrow, June 17, 2025, and to host a webcast at 8:00 a.m. ET. The company intends to issue a press release prior to the start of the event. Investor Conference Call and Webcast The live webcast will be available on the Events & Presentations page of the Investors & Media section of Dyne's website, and a replay will be accessible for 90 days followin
- DYNE-101 in DM1: Dyne plans to initiate global Registrational Expansion Cohort of ACHIEVE trial with registrational dose of 6.8 mg/kg Q8W following study data showing splicing correction and robust and sustained functional improvements; potential to support H1 2026 submission for U.S. Accelerated Approval - - DYNE-251 in Exon 51 DMD: Based on recent FDA feedback, pursuing U.S. Accelerated Approval with dystrophin as surrogate endpoint; data from ongoing Registrational Expansion Cohort in DELIVER trial expected late 2025 with potential to support early 2026 regulatory submission - - Investor event today, January 10th at 8:00 a.m. ET - WALTHAM, Mass., Jan. 10, 2025 (GLOBE NE
WALTHAM, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced it plans to report new clinical data from the Phase 1/2 ACHIEVE clinical trial on January 10, 2025, and to host a webcast at 8:00 a.m. ET. The company intends to issue a press release prior to the start of the event. Investor Conference Call and Webcast The live webcast will be available on the Events & Presentations page of the Investors & Media section of Dyne's website, and a replay will be accessible for 90 days following
- John Cox, Industry Leader with Global Experience in Rare Disease Commercialization, Joins Dyne as President and CEO - WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the appointment of John Cox as president, chief executive officer (CEO) and a member of the Board of Directors, effective immediately. He succeeds Joshua Brumm, who has chosen to step down from these roles to pursue a career in healthcare investing. Mr. Brumm will serve as an advisor to Dyne to help ensure a seamles
- Appointment Expands Dyne's Development Team as Company Advances Multiple Programs into Clinical Trials - WALTHAM, Mass., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the appointment of Francesco Bibbiani, M.D., as senior vice president, head of development. Dr. Bibbiani brings more than two decades of experience across development, including a focus on rare neuromuscular diseases as well as Duchenne muscular dystrophy (DMD). "We are excited to welcome Francesco to Dyne's development
WALTHAM, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the appointment of Carlo Incerti, M.D., to its Board of Directors. Dr. Incerti has more than three decades of experience in the biopharmaceutical industry, including in rare disease drug development. "We are excited to have Carlo joining the Board as we advance Dyne's programs into the clinic. He brings an extensive track record in global drug development, including from his time at Sanofi Genzyme where he played a leading role in pioneering ther
GLASGOW, Scotland, Sept. 21, 2021 /PRNewswire/ -- Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the appointment of Joshua T. Brumm as its new Independent Chairman, succeeding Satish Jindal. Amphista's CEO Dr Nicola Thompson said, "On behalf of the Amphista team I am thrilled to welcome someone of Josh's calibre to the Board. I look forward to working with Josh as we rapidly develop our pipeline of TPD therapeutics in oncology and beyond and unlock the full therapeutic potential of this exciting new modality. I would also like to thank our outgoing Chairman, Satish Jindal, who has tirelessly given his support as we have succe
Seasoned Clinical Leader Brings Deep Experience in Drug Development, Including Approval of an Oligonucleotide Therapy in Neuromuscular Disease WALTHAM, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the appointment of Wildon Farwell, M.D., MPH, as chief medical officer. Dr. Farwell brings expertise in clinical development and medical affairs in neuromuscular diseases and oligonucleotide therapies. “Wildon brings tremendous clinical experience and has played a leading role in the development of multipl
Dr. Dugar Brings Over 20 Years of Experience in Medical Affairs, Clinical and Commercial Development, and Real-World Evidence, Including in Rare Muscle Disease WALTHAM, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the appointment of Ashish Dugar, Ph.D., MBA, as senior vice president, global head of medical affairs. Dr. Dugar brings over 20 years of broad experience across medical affairs, clinical and commercial development, and real-world evidence (RWE) generation. “We are thrilled to welcome Ash to
SC 13G/A - Dyne Therapeutics, Inc. (0001818794) (Subject)
SC 13G/A - Dyne Therapeutics, Inc. (0001818794) (Subject)
SC 13G/A - Dyne Therapeutics, Inc. (0001818794) (Subject)
SC 13G - Dyne Therapeutics, Inc. (0001818794) (Subject)
SC 13G/A - Dyne Therapeutics, Inc. (0001818794) (Subject)
SC 13G/A - Dyne Therapeutics, Inc. (0001818794) (Subject)
SC 13G - Dyne Therapeutics, Inc. (0001818794) (Subject)
SC 13G/A - Dyne Therapeutics, Inc. (0001818794) (Subject)
SC 13G - Dyne Therapeutics, Inc. (0001818794) (Subject)
SC 13G/A - Dyne Therapeutics, Inc. (0001818794) (Subject)